Gilead Sciences to Acquire Repare Therapeutics' RP-3467 for Up to $30M

Gilead Sciences has acquired Repare Therapeutics' RP-3467, a polymerase theta ATPase inhibitor, for up to $30m. The deal includes a $25m upfront payment and up to $5m upon completion of technology transfer activities. The acquisition has increased Repare's cash reserves, raising the estimate for shareholder payments to $2.20 per common share upon closing the arrangement transaction. RP-3467 is a potent small molecule inhibitor of Polθ, linked to breast cancer gene mutations and other genomic alterations.